Aytu Biopharma (AYTU) EPS (Weighted Average and Diluted) (2020 - 2026)
Aytu Biopharma (AYTU) reported EPS (Weighted Average and Diluted) of -$0.53 for Q1 2026, down 365.0% year-over-year from $0.2 in Q1 2025, and up 49.52% quarter-over-quarter from -$1.05 in Q4 2025.
Aytu Biopharma (AYTU) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Aytu Biopharma (AYTU) has 7 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.53 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.53, down 365.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.46 (down 111.59% YoY), and the FY2023 annual result was -$5.11, up 93.1% from the prior year.
- EPS (Weighted Average and Diluted) improved to -$0.53 in Q1 2026 per AYTU's latest filing, from -$1.05 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $0.2 in Q1 2025 and troughed at -$35.9 in Q1 2022.
- A 5-year average of -$3.35 and a median of -$0.41 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2022 and 2025: EPS (Weighted Average and Diluted) sank 663.64% in 2022, then soared 148.78% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$2.15 in 2022, then surged by 98.14% to -$0.04 in 2023, then tumbled by 600.0% to -$0.28 in 2024, then sank by 275.0% to -$1.05 in 2025, then surged by 49.52% to -$0.53 in 2026.
- Business Quant data shows AYTU's EPS (Weighted Average and Diluted) at -$0.53 in Q1 2026, -$1.05 in Q4 2025, and -$0.08 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 0.31 |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 1.42 |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 5.82 |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 0.02 |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 1.91 |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 0.11 |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -0.40 |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 1.80 |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -0.40 |
| 10 | Aytu Biopharma | 24.18 Mn | -2.54 Mn | 7.60 Mn | -0.53 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.53 |
| Dec 31, 2025 | -1.05 |
| Sep 30, 2025 | -0.08 |
| Mar 31, 2025 | 0.20 |
| Dec 31, 2024 | -0.28 |
| Sep 30, 2024 | -0.20 |
| Mar 31, 2024 | -0.41 |
| Dec 31, 2023 | -0.04 |
| Sep 30, 2023 | -1.36 |
| Jun 30, 2023 | -0.40 |
| Mar 31, 2023 | -1.93 |
| Dec 31, 2022 | -2.15 |
| Sep 30, 2022 | -0.28 |
| Jun 30, 2022 | -5.88 |
| Mar 31, 2022 | -35.90 |
| Dec 31, 2021 | -8.74 |
| Sep 30, 2021 | -21.76 |
| Jun 30, 2021 | -0.77 |
| Dec 31, 2020 | -0.72 |
| Sep 30, 2020 | -0.35 |